238 related articles for article (PubMed ID: 29415891)
41. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
Kumar AJ; Vassilev P; Loren AW; Luger SM; Reshef R; Gill S; Smith J; Goldstein SC; Hexner E; Stadtmauer EA; Porter D; Frey NV
Am J Hematol; 2016 Jun; 91(4):426-9. PubMed ID: 26820493
[TBL] [Abstract][Full Text] [Related]
42. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
Ho VT; Kim HT; Kao G; Cutler C; Levine J; Rosenblatt J; Joyce R; Antin JH; Soiffer RJ; Ritz J; Avigan D; Alyea EP
Am J Hematol; 2014 Dec; 89(12):1092-6. PubMed ID: 25132538
[TBL] [Abstract][Full Text] [Related]
43. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
44. T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
Sano H; Mochizuki K; Kobayashi S; Ohara Y; Ito M; Waragai T; Takahashi N; Ikeda K; Ohto H; Kikuta A
Int J Hematol; 2018 Jul; 108(1):76-84. PubMed ID: 29508228
[TBL] [Abstract][Full Text] [Related]
45. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.
Ciceri F; Labopin M; Aversa F; Rowe JM; Bunjes D; Lewalle P; Nagler A; Di Bartolomeo P; Lacerda JF; Lupo Stanghellini MT; Polge E; Frassoni F; Martelli MF; Rocha V;
Blood; 2008 Nov; 112(9):3574-81. PubMed ID: 18606875
[TBL] [Abstract][Full Text] [Related]
46. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.
Vogt V; Schick J; Ansprenger C; Braeu M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
J Immunother; 2014; 37(6):331-47. PubMed ID: 24911794
[TBL] [Abstract][Full Text] [Related]
47. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.
Kinoshita H; Cooke KR; Grant M; Stanojevic M; Cruz CR; Keller M; Fortiz MF; Hoq F; Lang H; Barrett AJ; Liang H; Tanna J; Zhang N; Shibli A; Datar A; Fulton K; Kukadiya D; Zhang A; Williams KM; Dave H; Dome JS; Jacobsohn D; Hanley PJ; Jones RJ; Bollard CM
Blood Adv; 2022 Apr; 6(8):2520-2534. PubMed ID: 35244681
[TBL] [Abstract][Full Text] [Related]
48. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.
Ge C; Li R; Song H; Geng T; Yang J; Tan Q; Song L; Wang Y; Xue Y; Li Z; Dong S; Zhang Z; Zhang N; Guo J; Hua L; Chen S; Song X
BMC Cancer; 2017 Dec; 17(1):884. PubMed ID: 29268708
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
50. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
Lulla PD; Naik S; Vasileiou S; Tzannou I; Watanabe A; Kuvalekar M; Lulla S; Carrum G; Ramos CA; Kamble R; Hill L; Randhawa J; Gottschalk S; Krance R; Wang T; Wu M; Robertson C; Gee AP; Chung B; Grilley B; Brenner MK; Heslop HE; Vera JF; Leen AM
Blood; 2021 May; 137(19):2585-2597. PubMed ID: 33270816
[TBL] [Abstract][Full Text] [Related]
51. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
52. Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.
Bai Y; Zheng JE; Wang N; Cai HH; Zhai LN; Wu YH; Wang F; Jin RM; Zhou DF
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):689-693. PubMed ID: 26489623
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease.
Curley C; Hill GR; McLean A; Kennedy GA
Int J Lab Hematol; 2014 Apr; 36(2):197-204. PubMed ID: 24112249
[TBL] [Abstract][Full Text] [Related]
55. Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes.
Mo XD; Kong J; Zhao T; Xu LP; Zhang XH; Liu DH; Wang Y; Chen H; Yan CH; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2023-8. PubMed ID: 25196855
[TBL] [Abstract][Full Text] [Related]
56. Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
Koh H; Nakamae H; Hagihara K; Nakane T; Manabe M; Hayashi Y; Nishimoto M; Umemoto Y; Nakamae M; Hirose A; Inoue E; Inoue A; Yoshida M; Bingo M; Okamura H; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Ohsawa M; Hino M
J Exp Clin Cancer Res; 2011 Apr; 30(1):36. PubMed ID: 21477348
[TBL] [Abstract][Full Text] [Related]
57. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ
Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951
[TBL] [Abstract][Full Text] [Related]
58. 5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia - a summary.
Zhang X; Yang J; Zhang G; Song L; Su Y; Shi Y; Zhang M; He J; Song D; Lv F; Wu P; Wang H; Wang T; Zhang Y; Liu H; Lu P
Immunotherapy; 2020 Jan; 12(1):63-74. PubMed ID: 31914839
[No Abstract] [Full Text] [Related]
59. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
60. The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.
Khanuntong S; Kuptawintu P; Upaisilpsathaporn K; Poolchareon A; Bunworasate U; Hirankarn N
HLA; 2016 Jun; 87(6):422-31. PubMed ID: 27273744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
